Radionuclide Therapy of Painful Bone Metastases—A Comparative Study Between Consecutive Radionuclide Infusions, Combination With Chemotherapy, and Radionuclide Infusions Alone: An In Vivo Comparison of Their Effectiveness. (December 2013)

• Record Type: Journal Article
• Authors: Sideras, Panagiotis A.; Stavraka, Anastasia; Gouliamos, Athanasios; Limouris, Georgios S.
• Is Part Of: American journal of hospice & palliative care. Volume 30:Number 8(2013)
• Page Start: 745
• Page End: 751
• Publication Date: 2013-12
• Subjects: consecutive radionuclide treatment -- rhenium-186 HEDP -- 89strontium-chloride -- bone metastases -- pain palliation -- breast and prostate cancer; Hospice care -- Periodicals; Palliative treatment -- Periodicals; 362.175
• DOI: 10.1177/1049909112469719
• Languages: English
• ISSNs: 1049-9091

Abstract

Radionuclides have been long used for the palliation of skeletal-related metastatic pain. They are almost invariably used as the last resource for pain palliation. Their use as single agents with dose escalations, in combination with biphosphonates or chemotherapy is well known in the peer-reviewed literature; however, little is known about the combination between different agents. In our study, we used consecutive administration of 2 different radionuclides such as 186 Re-1, 1-hydroxyethylidenediphosphonate ( 186 Re-HEDP) and 89 Strontium Chloride ( 89 Sr-Cl) separated by adequate period of time to allow bone marrow recovery in patients with high chance of bone pain relapse and compared it with 89 Sr-Cl and chemotherapy group and 186 Re-HEDP with bisphosphonates. The end result was that treatment with consecutive radionuclides was much more effective and safe than the other 2 groups.